{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:36:49Z","timestamp":1790311009400,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yazd University of Medical Sciences","award":["7867"],"award-info":[{"award-number":["7867"]}]},{"name":"Yazd University of Medical Sciences","award":["7867"],"award-info":[{"award-number":["7867"]}]},{"name":"Yazd University of Medical Sciences","award":["7867"],"award-info":[{"award-number":["7867"]}]},{"name":"Yazd University of Medical Sciences","award":["7867"],"award-info":[{"award-number":["7867"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher\u2019s exact test, <jats:italic>t<\/jats:italic> test, and logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (<jats:italic>P<\/jats:italic> = 0.003).\u00a0Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (<jats:italic>P<\/jats:italic> = 0.86).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02548-2","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:03:22Z","timestamp":1647691402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Does Losartan reduce the severity of COVID-19 in hypertensive patients?"],"prefix":"10.1186","volume":"22","author":[{"given":"Mohammadreza","family":"Mirjalili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moslem Taheri","family":"Soodejani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Raadabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,19]]},"reference":[{"issue":"2","key":"2548_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/v12020135","volume":"12","author":"LE Gralinski","year":"2020","unstructured":"Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. https:\/\/doi.org\/10.3390\/v12020135.","journal-title":"Viruses"},{"issue":"1","key":"2548_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/msm.925364","volume":"8","author":"MS Alshahrani","year":"2018","unstructured":"Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):1\u201310. https:\/\/doi.org\/10.12659\/msm.925364.","journal-title":"Ann Intensive Care"},{"issue":"10229","key":"2548_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"Lancet"},{"issue":"7","key":"2548_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.2337\/dc20-0598","volume":"43","author":"Q Shi","year":"2020","unstructured":"Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes care. 2020;43(7):1382\u201391. https:\/\/doi.org\/10.2337\/dc20-0598.","journal-title":"Diabetes care"},{"issue":"6","key":"2548_CR5","doi-asserted-by":"publisher","first-page":"e14-e8","DOI":"10.1016\/j.jinf.2020.03.005","volume":"80","author":"K Liu","year":"2020","unstructured":"Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infection. 2020;80(6):e14\u20138. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.005.","journal-title":"J Infection"},{"issue":"13","key":"2548_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239\u201342. https:\/\/doi.org\/10.1001\/jama.2020.2648.","journal-title":"Jama"},{"key":"2548_CR7","doi-asserted-by":"publisher","unstructured":"Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, et al. Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.08.25.21262623.","DOI":"10.1101\/2021.08.25.21262623"},{"issue":"1","key":"2548_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40203-020-00058-7","volume":"9","author":"R Nejat","year":"2021","unstructured":"Nejat R, Sadr AS. Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. In silico Pharmacol. 2021;9(1):1\u201322. https:\/\/doi.org\/10.1007\/s40203-020-00058-7.","journal-title":"In silico Pharmacol"},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-017-2427-0","volume":"19","author":"YM Arabi","year":"2018","unstructured":"Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-\u03b21b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:1\u201313. https:\/\/doi.org\/10.1186\/s13063-017-2427-0.","journal-title":"Trials."},{"key":"2548_CR10","doi-asserted-by":"crossref","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. Dexamethasone in Hospitalized Patients with Covid-19. 2021;384(8):693\u2013704. https:\/\/dx.doi.org\/10.1056%2FNEJMoa2021436.","DOI":"10.1056\/NEJMoa2021436"},{"issue":"21","key":"2548_CR11","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1111\/bph.15072","volume":"177","author":"C Scavone","year":"2020","unstructured":"Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: What\u2019s next? Br J Pharmacol. 2020;177(21):4813\u201324. https:\/\/doi.org\/10.1111\/bph.15072.","journal-title":"Br J Pharmacol"},{"key":"2548_CR12","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0457.v1","author":"AS Jazzi","year":"2020","unstructured":"Jazzi AS, Mahnam K, Hejazi SH, Damavandi MS, Sadeghi P, Zeinalian M, et al. Inhibition of viral macrodomain of covid-19 and human trpm2 by losartan. Preprint. 2020. https:\/\/doi.org\/10.20944\/preprints202003.0457.v1.","journal-title":"Preprint"},{"issue":"6","key":"2548_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1017\/ice.2020.80","volume":"41","author":"M Zeinalian","year":"2020","unstructured":"Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential protective role of losartan against coronavirus-induced lung damage. Infection Control Hosp Epidemiol. 2020;41(6):752\u20133. https:\/\/doi.org\/10.1017\/ice.2020.80.","journal-title":"Infection Control Hosp Epidemiol"},{"issue":"19","key":"2548_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","volume":"106","author":"ME Flacco","year":"2020","unstructured":"Flacco ME, Martellucci CA, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519\u201324. https:\/\/doi.org\/10.1136\/heartjnl-2020-317336.","journal-title":"Heart"},{"issue":"2","key":"2548_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/fvl.10.4","volume":"5","author":"BA Wevers","year":"2010","unstructured":"Wevers BA. Hoek Lvd. Renin\u2013angiotensin system in human coronavirus pathogenesis. Future Virol. 2010;5(2):145\u201361. https:\/\/doi.org\/10.2217\/fvl.10.4.","journal-title":"Future Virol"},{"key":"2548_CR16","doi-asserted-by":"publisher","unstructured":"Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012. https:\/\/doi.org\/10.1155\/2012\/307315.","DOI":"10.1155\/2012\/307315"},{"issue":"2","key":"2548_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0163-7258(97)82002-5","volume":"74","author":"M McIntyre","year":"1997","unstructured":"McIntyre M, Caffe S, Michalak R, Reid J. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Therap. 1997;74(2):181\u201394. https:\/\/doi.org\/10.1016\/S0163-7258(97)82002-5.","journal-title":"Pharmacol Therap"},{"issue":"3","key":"2548_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.21037\/hbsn.2016.02.06","volume":"5","author":"ZA Salama","year":"2016","unstructured":"Salama ZA, Sadek A, Abdelhady AM, Darweesh SK, Morsy SA, Esmat G. Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatob Surg Nutr. 2016;5(3):249.","journal-title":"Hepatob Surg Nutr"},{"issue":"3","key":"2548_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ajpath.2017.11.006","volume":"188","author":"SL Sellers","year":"2018","unstructured":"Sellers SL, Milad N, Chan R, Mielnik M, Jermilova U, Huang PL, et al. Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1\u2013Independent Activation of Endothelial Function. Am J Pathol. 2018;188(3):574\u201385. https:\/\/doi.org\/10.1016\/j.ajpath.2017.11.006.","journal-title":"Am J Pathol"},{"issue":"6","key":"2548_CR20","doi-asserted-by":"publisher","first-page":"e0218471","DOI":"10.1371\/journal.pone.0218471","volume":"14","author":"JA Choi","year":"2019","unstructured":"Choi JA, Kim J-E, Ju H-h, Lee J, Jee D, Park CK, et al. The effects of losartan on cytomegalovirus infection in human trabecular meshwork cells. Plos one. 2019;14(6):e0218471. https:\/\/doi.org\/10.1371\/journal.pone.0218471.","journal-title":"Plos one"},{"issue":"5","key":"2548_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"JS Morse","year":"2020","unstructured":"Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730. https:\/\/dx.doi.org\/10.1002%2Fcbic.202000047.","journal-title":"Chembiochem"},{"issue":"5","key":"2548_CR22","doi-asserted-by":"publisher","first-page":"e96353","DOI":"10.1371\/journal.pone.0096353","volume":"9","author":"M Ivanov","year":"2014","unstructured":"Ivanov M, Mihailovi\u0107-Stanojevi\u0107 N, Gruji\u0107 Milanovi\u0107 J, Jovovi\u0107 \u0110, Markovi\u0107-Lipkovski J, \u0106irovi\u0107 S, et al. Losartan improved antioxidant defense, renal function and structure of postischemic hypertensive kidney. PloS one. 2014;9(5):e96353. https:\/\/doi.org\/10.1371\/journal.pone.0096353.","journal-title":"PloS one"},{"key":"2548_CR23","doi-asserted-by":"publisher","unstructured":"Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Zeinalian M, et al. The molecular story of COVID-19; NAD+ depletion addresses all questions in this infection. 2020. Kouhpayeh, S.; Shariati, L.; Boshtam, M.; Rahimmanesh, I.; Mirian, M.; Zeinalian, M.; Salari-jazi, A.; Khanahmad, N.; Damavandi, M.S.; Sadeghi, P.; Khanahmad, H. The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection. Preprints 2020, 2020030346 https:\/\/doi.org\/10.20944\/preprints202003.0346.v1.","DOI":"10.20944\/preprints202003.0346.v1"},{"key":"2548_CR24","doi-asserted-by":"crossref","unstructured":"Covid C, Team R, COVID C, Team R, COVID C, Team R, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)\u2014United States, February 12\u2013March 16, 2020. Morbidity and mortality weekly report. 2020;69(12):343. https:\/\/dx.doi.org\/10.15585%2Fmmwr.mm6912e2.","DOI":"10.15585\/mmwr.mm6912e2"},{"key":"2548_CR25","unstructured":"TNCPERE T. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)-China, 2020. 2020."},{"issue":"6","key":"2548_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.cmi.2020.04.012","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767\u201372. https:\/\/doi.org\/10.1016\/j.cmi.2020.04.012.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"2548_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2020.1017.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2548_CR28","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1002\/ehf2.13462","volume":"8","author":"V Nuzzi","year":"2021","unstructured":"Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, et al. The prognostic value of serial troponin measurements in patients admitted for COVID-19. ESC Heart Failure. 2021;8(5):3504\u201311. https:\/\/doi.org\/10.1002\/ehf2.13462.","journal-title":"ESC Heart Failure"},{"issue":"1","key":"2548_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microb Infect. 2020;9(1):757\u201360. https:\/\/doi.org\/10.1080\/22221751.2020.1746200.","journal-title":"Emerg Microb Infect"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02548-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T12:09:27Z","timestamp":1647691767000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02548-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,19]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02548-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,19]]},"assertion":[{"value":"22 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The article\u2019s proposal was approved by the ethics committee of Shahid Sadoughi University of Medical Sciences with the ID of IR.SSU.REC.1399.101. Due to the retrospective nature of the study, no study specific consent form was used. However, patients admitted to our hospital are asked to sign a general consent upon admission, which covers the collection of patient data and publication of these results. Therefore, the individual\u2019s informed consent was waived by the above ethics committee.  We received administrative permission from (Secretary of University\/Regional Research Ethics Committee Shahid Sadoughi University of Medical Sciences) to access and use the data. Data used in the study were anonymized.  The ethics committee approved this procedure with the above ethical code.  The present study was conducted in terms of the principles of the revised Declaration of Helsinki, which waived requirement for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"All authors declare that they have no conflict of interest regarding this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"116"}}